These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 7271235

  • 1. L-dopa-resistant Parkinsonism due to dopa decarboxylase deficiency?
    Jankovic J.
    Ann Neurol; 1981 Jul; 10(1):64-5. PubMed ID: 7271235
    [No Abstract] [Full Text] [Related]

  • 2. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
    Cinca I, Serbănescu A, Tudorache B.
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982 Jul; 27(4):261-70. PubMed ID: 6222452
    [No Abstract] [Full Text] [Related]

  • 3. [Pharmacokinetic and pharmacodynamic aspects of L-DOPA treatment and dopadecarboxilase inhibitors and dopaminergic antagonists in Parkinson's disease (author's transl)].
    García de Yébenes J, Avila C, Bazán E, García E, Gervás J, Maseda C, Mena M, Muradas V, Ramos JA.
    Med Clin (Barc); 1982 Apr 01; 78(7):259-64. PubMed ID: 7087591
    [No Abstract] [Full Text] [Related]

  • 4. [Risks in the treatment of parkinsonism with l-dopa and a dopa decarboxylase inhibitor].
    Jörg J.
    Med Welt; 1979 Nov 16; 30(46):1740-2. PubMed ID: 537499
    [No Abstract] [Full Text] [Related]

  • 5. [Progress in the therapy of parkinsonism with L-dopa: inhibition of dopa decarboxylase].
    Nurzia A.
    Clin Ter; 1975 Feb 15; 72(3):289-95. PubMed ID: 1132216
    [No Abstract] [Full Text] [Related]

  • 6. [Psychological changes in parkinsonian patients during L-DOPA, amantidine, and L-DOPA + IDC treatment (author's transl)].
    Puca FM, Megna GF, Masi G, Specchio LM.
    Riv Patol Nerv Ment; 1974 Oct 15; 95(5):676-84. PubMed ID: 4470268
    [No Abstract] [Full Text] [Related]

  • 7. Aromatic L-amino acid decarboxylase deficiency in Taiwan.
    Lee HF, Tsai CR, Chi CS, Chang TM, Lee HJ.
    Eur J Paediatr Neurol; 2009 Mar 15; 13(2):135-40. PubMed ID: 18567514
    [Abstract] [Full Text] [Related]

  • 8. Drug therapy of parkinsonism.
    Bianchine JR.
    N Engl J Med; 1976 Oct 07; 295(15):814-8. PubMed ID: 958277
    [No Abstract] [Full Text] [Related]

  • 9. Levodopa-responsive aromatic L-amino acid decarboxylase deficiency.
    Chang YT, Sharma R, Marsh JL, McPherson JD, Bedell JA, Knust A, Bräutigam C, Hoffmann GF, Hyland K.
    Ann Neurol; 2004 Mar 07; 55(3):435-8. PubMed ID: 14991824
    [Abstract] [Full Text] [Related]

  • 10. [L-dopa-decarboxylase inhibitor combination preparation (Sinemet) in parkinsonism and syndromes imitating parkinsonism. 1 year's experience with 34 patients].
    Holmsen R.
    Tidsskr Nor Laegeforen; 1976 Feb 10; 96(4):225, 234-6. PubMed ID: 1251394
    [No Abstract] [Full Text] [Related]

  • 11. Age-dependent depressor effect of L-dopa in dogs with inhibition of extracerebral dopa decarboxylase.
    Wilke WL.
    Pediatr Res; 1983 Nov 10; 17(11):924-5. PubMed ID: 6359046
    [Abstract] [Full Text] [Related]

  • 12. [Risks of modern therapy for parkinsonism, and their consequences (author's transl)].
    Jörg J, Kleine D.
    Nervenarzt; 1979 Jan 10; 50(1):33-42. PubMed ID: 424033
    [No Abstract] [Full Text] [Related]

  • 13. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration.
    Lee WY, Lee EA, Jeon MY, Kang HY, Park YG.
    Exp Neurol; 2006 Jan 10; 197(1):215-24. PubMed ID: 16269145
    [Abstract] [Full Text] [Related]

  • 14. Perturbed pattern of catecholamine-containing neurons in mutant Drosophila deficient in the enzyme dopa decarboxylase.
    Budnik V, Martin-Morris L, White K.
    J Neurosci; 1986 Dec 10; 6(12):3682-91. PubMed ID: 3098930
    [Abstract] [Full Text] [Related]

  • 15. Peripheral aromatic L-amino acids decarboxylase inhibitor in Parkinsonism. I. Effect on O-methylated metabolites of L-dopa-2- 14 C.
    Messiha FS, Hsu TH, Bianchine JR.
    J Clin Invest; 1972 Feb 10; 51(2):452-5. PubMed ID: 5009125
    [Abstract] [Full Text] [Related]

  • 16. [New directions in contemporary pharmacotherapy of parkinsonism (review)].
    Kurako IuL, Volianskiĭ VE.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984 Feb 10; 84(9):1401-6. PubMed ID: 6150591
    [No Abstract] [Full Text] [Related]

  • 17. Aromatic L-amino acid decarboxylase enzyme activity in deficient patients and heterozygotes.
    Verbeek MM, Geurtz PB, Willemsen MA, Wevers RA.
    Mol Genet Metab; 2007 Apr 10; 90(4):363-9. PubMed ID: 17240182
    [Abstract] [Full Text] [Related]

  • 18. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
    Silva MA, Mattern C, Häcker R, Tomaz C, Huston JP, Schwarting RK.
    Synapse; 1997 Dec 10; 27(4):294-302. PubMed ID: 9372552
    [Abstract] [Full Text] [Related]

  • 19. Do's and don'ts for the patient on levodopa therapy.
    Langan RJ, Cotzias GC.
    Am J Nurs; 1976 Jun 10; 76(6):917-8. PubMed ID: 1046914
    [No Abstract] [Full Text] [Related]

  • 20. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats.
    Sánchez-Pernaute R, Harvey-White J, Cunningham J, Bankiewicz KS.
    Mol Ther; 2001 Oct 10; 4(4):324-30. PubMed ID: 11592835
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.